Ergothioneine, Mushrooms, and Dopaminergic Neuron Survival

Mushrooms & Parkinson's Disease

35 PD patients

In a 2016 Japanese biomarker study, 35 Parkinson's disease patients had significantly lower serum ergothioneine than 15 healthy controls — the finding that launched a decade of mechanistic investigation into this mushroom compound.

Hatano et al., J Neurology, Neurosurgery & Psychiatry, 2016

OCTN1-dependent

ergothioneine protection of human iPSC dopaminergic neurons is eliminated when OCTN1 is blocked (Ng 2024)

3 model systems

Drosophila, mouse, and human LRRK2 G2019S neurons all showed protection in Tng 2025

King oyster

highest ergothioneine content per gram among common culinary mushroom species

Hatano et al., J Neurology, Neurosurgery & Psychiatry, 2016

View as image ↗

Parkinson's disease destroys a specific type of brain cell: the dopaminergic neuron in the substantia nigra. The question this article addresses is whether ergothioneine — a dietary compound found almost exclusively in mushrooms — has a meaningful role in protecting those exact cells, and whether its depletion in Parkinson's patients reflects something biologically important. It is part of the broader mushrooms and brain health cluster and is the most mechanistically detailed article in the series on mushrooms and Parkinson's disease.

The evidence threads together from epidemiology through cell biology: PD patients are depleted of ergothioneine. The human body has a dedicated transport mechanism (OCTN1) that specifically moves ergothioneine into dopaminergic neurons. A 2024 study demonstrated in actual PD patient-derived neurons that this transport is required for the protective effect. A 2025 study validated the same outcome across three independent biological systems. And a 2024 hypothesis paper argued that this depletion may not be a consequence of disease — it may be a contributor.

The First Clue: Parkinson's Patients Are Running Low

In 2016, Hatano et al. ran a broad metabolomic screen — measuring hundreds of compounds simultaneously — in blood samples from 35 people with idiopathic Parkinson's disease and 15 healthy age-matched controls.^[1] Among the compounds that came up significantly lower in the Parkinson's group was ergothioneine.

The study was small. The right interpretation of 50 people is hypothesis generation, not confirmation. But the finding was specific: in Parkinson's disease, circulating ergothioneine is depleted. And ergothioneine is a compound the human body gets almost entirely from mushrooms.

Five years later, Cheah et al. tested the same relationship at a scale that demanded attention.^[2] Their Singapore Memory Clinic study enrolled 470 elderly subjects and measured plasma ergothioneine alongside a comprehensive neurodegeneration assessment — brain imaging, cognitive testing, cerebrovascular markers, clinical diagnoses. Low plasma ergothioneine was associated with neurodegeneration markers (brain atrophy, white matter lesions), cerebrovascular disease, and Parkinson's disease burden. The finding held across multiple dimensions of neurological decline, not just PD specifically.

Together, Hatano 2016 and Cheah 2021 establish the pattern: the sicker the brain, the lower the ergothioneine. The question is what that pattern means causally. For the full epidemiological story with the 5-year longitudinal data, see Ergothioneine and Parkinson's Disease Risk: Evidence Review.

Cause or Consequence? Why That Question Matters

Low ergothioneine in PD patients could mean three things:

The disease depletes ergothioneine. Neurodegeneration generates oxidative stress; ergothioneine, as an antioxidant, gets consumed defending the neurons. The depletion is downstream of disease, not upstream of it.

Low ergothioneine contributes to the disease. Dopaminergic neurons that are normally protected by ergothioneine become more vulnerable when supplies run low. The depletion is upstream.

Both are true. A reinforcing cycle: dopaminergic neurons under oxidative stress consume ergothioneine faster; lower ergothioneine means less protection against the next oxidative insult; the cycle accelerates.

The observational human data cannot distinguish between these. Cross-sectional cohorts measure a snapshot; longitudinal cohorts (like Tanaka 2022's 5-year follow-up) can show that low ergothioneine predicts worse outcomes, which is consistent with causality but doesn't prove it. What can move the needle toward causality is mechanistic evidence: does ergothioneine actually do something protective in the relevant cells, via a pathway that makes biological sense? It does.

The Biological Route: How Ergothioneine Reaches Dopaminergic Neurons

Ergothioneine does not drift passively into cells. It enters via a dedicated transporter protein called OCTN1, which actively pulls ergothioneine across cell membranes into tissues that express it.

This matters for the Parkinson's story specifically because of where OCTN1 is expressed. Halliwell et al.'s 2022 comprehensive review in Neurochemistry International documented that OCTN1 is expressed in brain tissue and in dopaminergic neurons in the substantia nigra.^[3] The cells that Parkinson's disease destroys are equipped with a dedicated mechanism to accumulate ergothioneine.

Halliwell's review also established that ergothioneine crosses the blood-brain barrier via OCTN1, reaching concentrations in brain tissue that are biologically active as an antioxidant. Inside cells, ergothioneine neutralizes reactive oxygen species and chelates metal ions — particularly iron, which is elevated in the substantia nigra of PD patients and catalyzes the most damaging forms of oxidative chemistry. The review confirmed across multiple studies that PD patients have lower ergothioneine, and assembled the mechanistic case for why that depletion would specifically matter for dopaminergic neurons.

The mechanistic logic is internally consistent. Dopaminergic neurons generate reactive oxygen species during dopamine synthesis and metabolism. They are bathed in iron. They are among the most oxidatively stressed cells in the brain. They have a dedicated uptake mechanism for the one dietary antioxidant that the body does not produce. Their depletion of that antioxidant in disease maps onto the expected downstream consequences of reduced protection.

For more on the OCTN1 transporter and its broader significance across tissues, see OCTN1: The Dedicated Transporter That Proves Ergothioneine Matters.

Human Cell Proof of Concept: Patient-Derived Neurons With Parkinson's Genetics

The mechanistic case became considerably more direct in 2024. Ng et al. published a study in Antioxidants that used induced pluripotent stem cell (iPSC) technology to grow dopaminergic neurons from cells taken from actual Parkinson's disease patients carrying the LRRK2 G2019S mutation — one of the most common known genetic risk factors for PD.^[4]

The LRRK2 G2019S mutation means these were not generic human cells in a dish. They carried the specific genetic architecture associated with Parkinson's disease. Ng's team differentiated these iPSCs into dopaminergic neurons and exposed them to rotenone — a pesticide-derived mitochondrial toxin used to model the kind of dopaminergic injury that occurs in PD.

Ergothioneine protected the patient-derived neurons from rotenone toxicity. Then Ng's team asked the mechanism question directly: does OCTN1 matter? They added an OCTN1 inhibitor that blocks the transporter without otherwise interfering with ergothioneine. The protective effect disappeared. OCTN1 is required for ergothioneine to protect these neurons. The Halliwell 2022 mechanistic proposal was confirmed in human cells with actual PD genetics.

The study also demonstrated protection in human SH-SY5Y neuroblastoma cells treated with 6-OHDA (6-hydroxydopamine), a second chemical model of dopaminergic neuron injury used in Parkinson's research. The OCTN1-dependent mechanism held in both human cell systems tested.

This is the most direct human evidence available for the mechanism. Prior studies had used animal cells, or non-PD human cells, or had not tested the OCTN1 requirement. Ng 2024 used neurons with actual Parkinson's disease genetics and confirmed that removing the transporter eliminates the protection.

Three Systems, One Direction: The Tng 2025 Multi-Model Study

The Ng 2024 human iPSC finding was strengthened the following year by Tng et al., who published in the Journal of Neurochemistry a study that ran ergothioneine treatment in three Parkinson's disease models simultaneously.^[5]

The three systems were: Drosophila fruit flies carrying parkin and LRRK2 mutations (two different genetic models of PD), mouse Parkinson's disease models, and human LRRK2 G2019S iPSC-derived dopaminergic neurons.

Ergothioneine ameliorated pathological phenotypes in all three. The Drosophila with PD-associated mutations showed improved climbing scores — a behavioral readout of dopaminergic function — and reduced dopaminergic neuron loss. The mouse models showed reduced disease pathology. The human patient-derived neurons showed enhanced survival.

Each of these systems has limitations. Fruit flies do not have exactly human-equivalent dopaminergic systems. Mouse models of PD do not fully recapitulate the human disease course. Cell culture lacks the complexity of a living brain. But the fact that a compound produces the same protective direction across all three simultaneously — across different species, different genetic backgrounds, different experimental conditions — substantially reduces the probability that the result is a model-specific artifact.

The Tng 2025 study is the strongest experimental argument that ergothioneine actively protects dopaminergic neurons, not just that it correlates with better outcomes in populations. For a side-by-side view of all mushroom compounds with dopaminergic neuroprotection data, see Mushroom Compounds and Dopaminergic Neuron Protection.

The Deficiency Hypothesis and What It Means Dietarily

The final piece of the framework comes from Kell et al.'s 2024 review in Free Radical Biology and Medicine, which synthesized the epidemiology and mechanism into a formal hypothesis: that ergothioneine insufficiency, accumulating with age, may be a causally upstream factor in Parkinson's disease and other neurodegenerative diseases.^[6]

The Kell hypothesis rests on two observations working together. First, ergothioneine plasma levels decline with age. Part of this is behavioral — older adults eat fewer mushrooms. Part is biological — OCTN1 expression appears to decrease with age, reducing uptake efficiency even from the same dietary intake. The result is a compound depletion: less mushroom consumption and less efficient absorption from whatever is consumed.

Second, Parkinson's disease incidence rises sharply with age. The ergothioneine depletion curve and the PD incidence curve run in the same direction. Kell et al. proposed this overlap is not coincidental but potentially causal: as ergothioneine levels fall below the threshold needed to buffer oxidative stress in dopaminergic neurons, those neurons become progressively more vulnerable to the triggers of PD pathology.

This hypothesis remains unproven. No intervention trial has tested it. What it provides is a testable prediction with clear dietary implications. The most ergothioneine-rich common culinary mushrooms are king oyster (highest per gram), followed by shiitake, button, and cremini. These are widely available and relatively inexpensive. If the Kell hypothesis is directionally correct, regular consumption of ergothioneine-rich mushrooms is the most practical dietary lever available.

For a practical species-by-species guide to which mushrooms provide the most relevant compounds for brain protection, see Which Mushrooms Show Promise for Parkinson's? and Best Mushrooms for Brain Health in Older Adults.

What remains unknown: whether eating more mushrooms translates to sufficient plasma ergothioneine increase to produce neuroprotective effects, and whether those effects translate from laboratory models to human Parkinson's disease. No randomized trial has tested dietary ergothioneine in PD patients. The hypothesis is coherent; the evidence base is substantial for preclinical science; the clinical translation is unconfirmed.

The Bottom Line

Parkinson's disease patients consistently show lower ergothioneine levels than healthy controls, and the biological pathway connecting ergothioneine to dopaminergic neuron survival is well characterized: OCTN1-dependent transport into substantia nigra neurons, antioxidant activity against the oxidative stress of dopamine metabolism, and protective effects confirmed in human LRRK2 G2019S patient-derived iPSC neurons (Ng 2024). Multi-model validation across Drosophila, mouse, and human cells followed in 2025. Whether dietary ergothioneine from mushrooms translates to clinical neuroprotection in humans remains unstudied.

Frequently Asked Questions

Does ergothioneine deficiency cause Parkinson's disease?

Not proven, but the hypothesis has substantial support. Parkinson's patients consistently have lower plasma ergothioneine than healthy controls. A 2024 hypothesis paper by Kell et al. proposed that age-related ergothioneine depletion — from declining mushroom consumption and declining OCTN1 expression — may be a causal upstream factor. The human data is observational; no intervention trial has tested whether restoring ergothioneine reduces PD risk or progression.

How does ergothioneine protect dopamine neurons?

Ergothioneine enters dopaminergic neurons via the OCTN1 transporter, which is expressed in the substantia nigra. Inside neurons, it neutralizes reactive oxygen species produced during dopamine synthesis and chelates iron, which catalyzes oxidative damage in the substantia nigra. A 2024 study by Ng et al. confirmed this mechanism in human LRRK2 G2019S patient-derived iPSC dopaminergic neurons: blocking OCTN1 eliminated ergothioneine's protective effect entirely.

Can mushrooms prevent dopamine neuron loss?

In laboratory models, yes — ergothioneine from mushrooms protected dopaminergic neurons in Drosophila, mouse, and human iPSC models. In humans, there is no clinical trial evidence. Population studies show people with higher mushroom consumption and higher plasma ergothioneine tend to have better neurological outcomes, but this is observational data that cannot establish causation. The dietary connection is biologically plausible and mechanistically supported; it is not clinically proven.

What is the role of ergothioneine in Parkinson's disease?

Ergothioneine is a dietary antioxidant found almost exclusively in mushrooms. Its role in Parkinson's disease appears to be as a protective buffer for dopaminergic neurons: it enters these cells via OCTN1, scavenges reactive oxygen species, and chelates iron. Parkinson's patients are depleted of it. When given to PD model systems in the laboratory, it protects dopaminergic neurons from toxicity. Whether low ergothioneine contributes to PD or is depleted by it is still debated.

Why do Parkinson's patients have low ergothioneine levels?

Two possible reasons, which may both be true. First, Parkinson's disease pathology generates oxidative stress that consumes ergothioneine, depleting circulating levels as the disease progresses. Second, ergothioneine depletion may precede and contribute to disease: older adults eat fewer mushrooms, and OCTN1 expression appears to decline with age, reducing ergothioneine absorption. The Kell 2024 hypothesis paper proposed that this cumulative depletion leaves dopaminergic neurons more vulnerable to PD triggers.

Sources & References

1. 1RTHM-00784·Hatano, Taku et al. (2016). “Identification of novel biomarkers for Parkinson's disease by metabolomic technologies..” Journal of neurology.Study breakdown →PubMed →↩
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5RTHM-02195·Tng, Teddy J W et al. (2025). “Ergothioneine Treatment Ameliorates the Pathological Phenotypes of Parkinson's Disease Models..” Journal of neurochemistry.Study breakdown →PubMed →↩
6. 6. Source details for this reference are not yet available.